Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.
- NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_assertion description "[Poly(ADP-ribose) polymerase inhibitors (PARPi) are currently evaluated in clinical trials in combination with topoisomerase I (Top1) inhibitors against a variety of cancers, including colon carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.
- NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_assertion evidence source_evidence_literature NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.
- NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_assertion SIO_000772 23653048 NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.
- NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_assertion wasDerivedFrom befree-20140225 NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.
- NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_assertion wasGeneratedBy ECO_0000203 NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.
- befree-20140225 importedOn "2014-02-25" NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.